gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Myotubularin related protein 12

3-PAP, 3-phosphatase adapter subunit, 3-phosphatase adapter protein
Phosphatidylinositide 3-kinase-derived membrane-anchored phosphatidylinositides, such as phosphatidylinositol 3-phosphate (PtdIns(3)P), regulate diverse cellular processes. The protein encoded by this gene functions as an adaptor subunit in a complex with an active PtdIns(3)P 3-phosphatase. Alternatively spliced transcript variants have been identified, but their biological validity has not been determined. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: PAP, HAD, AGE, CAN, Inactive
Papers on 3-PAP
Organizational Variation in Implementation of an Evidence-Based Human Papillomavirus Intervention.
Crosby et al., Lexington, United States. In Am J Prev Med, Aug 2015
Given their historic focus on prevention, local health departments were selected as pilot sites to study implementation of 1-2-3 Pap in a public health setting and identify site-specific variations in its implementation.
Adoption of Evidence-Based Interventions in Local Health Departments: "1-2-3 Pap NC".
Luo et al., Greenville, United States. In Am J Prev Med, Aug 2015
This study was conducted by the North Carolina Public Health Practice-Based Research Network to identify factors associated with adoption of an evidence-based human papillomavirus video intervention, "1-2-3 Pap NC," in North Carolina LHDs.
A Cost Analysis of the 1-2-3 Pap Intervention.
Massoudi et al., United States. In Front Public Health Serv Syst Res, 2014
1-2-3 Pap is a video intervention tested and proven to increase HPV vaccination completion rates.
Designing for dissemination: lessons in message design from "1-2-3 pap".
Winterbauer et al., United States. In Health Commun, 2014
This article presents the case study of "1-2-3 Pap," a health communication intervention to improve human papillomavirus (HPV) vaccination uptake and Pap testing outcomes in Eastern Kentucky, and explores strategies used to disseminate this intervention to other populations in Kentucky, North Carolina, and West Virginia.
Mutation screening of PDZD2, GOLPH3, and MTMR12 genes in patients with schizophrenia.
Bespalova et al., In Psychiatr Genet, 2012
This study does not support the association of PDZD2, GOLPH3, and MTMR12 genes with schizophrenia.
Geranyl derivative of phloroacetophenone induces cancer cell-specific apoptosis through Bax-mediated mitochondrial pathway in MCF-7 human breast cancer cells.
Kim et al., KyŸngsan, South Korea. In Biol Pharm Bull, 2011
In the present study, we examined the cytotoxic activity of prenyl (3-PAP) and geranyl (3-GAP) derivatives of phloroacetophenone, and xanthohumol (XN), a prenyl-chalcone, in human breast cancer (MCF-7) and human sarcoma (HT1080) cell lines in vitro.
An exploration of Papanicolaou smear history and behavior of patients with newly diagnosed cervical cancer in Taiwan.
Lai et al., Taiwan. In Cancer Nurs, 2010
RESULTS: Of the 141 patients, 62 (44.0%) had never had a Pap smear before diagnosis, 10 (7.1%) did not know about the Pap smear, and only 30 (21%) reported having had more than 3 Pap smears in their lifetime.
Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Modesitt et al., Lexington, United States. In Obstet Gynecol, 2006
A subset of 435 patients received cytologic follow-up at our institution, with a median 3 Pap tests/patient (mean 4.25, range 1-24).
Hypothesis: the act of taking a Papanicolaou smear reduces the prevalence of human papillomavirus infection: a potential impact on the risk of cervical cancer.
Williamson et al., Columbia, United States. In Cancer Causes Control, 2003
METHODS: Among 1540 control women we compared prevalence rates of infection with specific HPVs known to cause cervical cancer among those who previously received 0, 1, 2 or > or = 3 Pap smears in their lifetimes.
Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP.
Mitchell et al., Melbourne, Australia. In Proc Natl Acad Sci U S A, 2003
Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP.
Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: identification of a myotubularin-related protein lacking catalytic activity.
Mitchell et al., Australia. In Proc Natl Acad Sci U S A, 2001
Here, we have cloned and characterized the cDNA encoding the human 3-phosphatase adapter subunit (3-PAP).
In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
Uckun et al., Minneapolis, United States. In Cancer Res, 1995
After 48 h no viable human OHS osteosarcoma cells were present in cultures containing TP-3-PAP as demonstrated by the absence of [3H]thymidine uptake into DNA.
Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Omacini et al., Venice, Italy. In Eur Urol, 1994
Progression of the disease to the bone occurred in 20 patients: in 17 PSA was the first indicator of progression, in the other 3 PAP anticipated PSA for a very short time (3-4 months), which was not of relevance to clinical decisions.
The adequacy of management of women with CIN 2 and CIN 3 Pap smear abnormalities.
Shelley et al., Sydney, Australia. In Med J Aust, 1993
OBJECTIVE: To assess the adequacy of management of Sydney women with Papanicolaou (Pap) smears showing cervical intraepithelial neoplasia (CIN) grades two and three.
Oral contraceptive use and cervical intraepithelial neoplasia.
Walton et al., Colombia. In J Clin Epidemiol, 1992
Cases were more likely to have been divorced (OR - 2.7), to be cigarette smokers (OR = 3.4), to have ever been pregnant (OR - 2.6), to have had more than 2 sex partners (OR = 5.0), to have reported having had a sexually transmitted disease (gonorrhea, chlamydia, herpes, venereal warts, or pelvic inflammatory disease) (OR = 2.9), and to have had at least 3 Pap smears in the 5 years prior to study recruitment (OR = 1.7).
share on facebooktweetadd +1mail to friends